Correction of a pathogenic gene mutation in human embryos
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Germline editing has been used for years in animals, including mice, rats, monkeys and many others, and experiments show that it can be done in both nonviable or viable human embryos as well 110-113 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [112]
In the citing paper
“Of the studies that have been conducted, the reported efficiencies of repair with templates in human embryos are very low (5,7,8).”
From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Orthwein, A. et al. Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science 344, 189–193 (2014)”
Cited work 10.1126/science.1248024 · retracted 2025-01-09 · notice 10.1126/science.adv1263 · this paper published 2017-08
Citations
Cites
1 retracted
Mitosis Inhibits DNA Double-Strand Break Repair to Guard Against Telomere Fusions
Orthwein, A., Fradet-Turcotte, A., Noordermeer, S. M., Canny, M. D., Brun, C. M., Strecker, J., Escribano-Diaz, C., & Durocher, D. (2014) · Science · doi:10.1126/science.1248024 · Cited by 319
RetractedA Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationAntoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Cited by
Items 201–300 of 948
Bridge Helix of Cas9 Modulates Target DNA Cleavage and Mismatch Tolerance
Babu, K., Amrani, N., Jiang, W., Yogesha, S. D., Nguyen, R., Qin, P. Z., & Rajan, R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01241 · Cited by 49
Khan, S. A., Khan, M., Iqbal, N., Khan, S. A., & Chou, K. (2020) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2020.104056 · Cited by 47
Progress Toward Zygotic and Germline Gene Drives in Mice
Pfitzner, C., White, M. A., Piltz, S., Scherer, M. A., Adikusuma, F., Hughes, J. N., & Thomas, P. Q. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0050 · Cited by 48
“31 Further, it has recently been reported that ‘‘interhomolog repair’’ (effectively the same process as gene drive homing) can occur in human embryos, 32 although concerns have been raised about the interpretation of these results.”
Ma, H., Martí‐Gutiérrez, N., Park, S.-W., Wu, J., Hayama, T., Darby, H., Dyken, C. V., Li, Y., Koski, A., Liang, D., et al. (2018) · Nature · doi:10.1038/s41586-018-0381-y · Cited by 47
Self-citationGenetics of BAG3: A Paradigm for Developing Precision Therapies for Dilated Cardiomyopathies
Qu, H., Feldman, A. M., & Hakonarson, H. H. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.027373 · Cited by 55
Kang, X., Caparas, C. I. N., Soh, B.-S., & Fan, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0477-4 · Cited by 58
Gene therapy for inherited arrhythmias
Bezzerides, V. J., Prondzynski, M., Carrier, L., & Pu, W. T. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa107 · Cited by 47
Development challenges associated with rAAV-based gene therapies
Bolt, M. W., Brady, J. T., Whiteley, L. O., & Khan, K. N. M. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.57 · Cited by 49
Restrictive cardiomyopathy: from genetics and clinical overview to animal modeling
Chintanaphol, M., Orgil, B., Alberson, N. R., Towbin, J. A., & Purevjav, E. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303108 · Cited by 50
“[81] repaired a heterozygous dominant mutation ofMYBC3, a mu-”
BackgroundCRISPR/Cas9: Regulations and challenges for law enforcement to combat its dual-use
Mir, T. U. G., Wani, A. K., Akhtar, N., & Shukla, S. (2022) · Forensic Science International · doi:10.1016/j.forsciint.2022.111274 · Cited by 57
Gene editing in human development: ethical concerns and practical applications
Rossant, J. (2018) · Development · doi:10.1242/dev.150888 · Cited by 50
“In terms of human germline-competent gene editing, there have been several additional studies demonstrating feasibility of gene correction in human diploid zygotes (Ma et al., 2017; Tang et al., 2017), as well as the demonstration that new base editing tools can be applied to human”
BackgroundTherapeutic genome editing in cardiovascular diseases
Nishiga, M., Qi, L. S., & Wu, J. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.003 · Cited by 44
Self-citationControl of gene doping in human and horse sports
Tozaki, T., & Hamilton, N. A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00267-5 · Cited by 48
Modeling rare diseases with induced pluripotent stem cell technology
Anderson, R. H., & Francis, K. R. (2018) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2018.01.001 · Cited by 53
Masset, H., Ding, J., Dimitriadou, E., Ardeshirdavani, A., Debrock, S., Tšuiko, O., Smits, K., Peeraer, K., Moreau, Y., Voet, T., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac134 · Cited by 38
The Potential of Nanotechnology in Medically Assisted Reproduction
Remião, M. H., Segatto, N. V., Pohlmann, A. R., Guterres, S. S., Seixas, F. K., & Collares, T. V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00994 · Cited by 47
“Monogenic diseases may be easily corrected using gene therapy, as they are caused by a single defective gene (Ma et al., 2017).”
BackgroundMethodCollier, A. J., & Rugg‐Gunn, P. J. (2018) · BioEssays · doi:10.1002/bies.201700239 · Cited by 49
Reasons for being in favour of or against genome modification: a survey of the Dutch general public
Hendriks, S., Giesbertz, N. A. A., Bredenoord, A. L., & Repping, S. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy008 · Cited by 55
“Such a study is timely considering that CRISPR/Cas9 brings clinical applications of germline genome ....................................................................................... Table I Characteristics of respondents in the survey on views of the Dutch general public on the use of genome modification.”
BackgroundInfluentialPathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives
Zampieri, M., Berteotti, M., Ferrantini, C., Tassetti, L., Gabriele, M., Tomberli, B., Castelli, G., Cappelli, F., Stefàno, P., Marchionni, N., et al. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00523-0 · Cited by 29
“[89] Recent developments in precise genome-editing techniques and their successful applications in animalmodels have provided different option for correcting human germline mutations.”
Backgroundde Vries, A. R. G., Couwenberg, L. G. F., van den Broek, M. A., Cortés, P. D. L. T., ter Horst, J., Pronk, J. T., & Daran, J.-M. G. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1216 · Cited by 44
“Reports of LOH after targeting a heterozygous allele in human embryos despite availability of an adequate repair fragment, are consistent with Cas9induced LOH extending beyond the targeted locus, as described here (41).”
BackgroundPhenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging
Muresan, I. D., & Agoşton-Coldea, L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09931-1 · Cited by 40
“[24] have correctedMYBPC3mutation in human germ cells, using clustered regularly interspersed short palindromic repeats (CRISPR-Cas9).”
BackgroundMultiplex precise base editing in cynomolgus monkeys
Zhang, W., Aida, T., del Rosario, R. C. H., Wilde, J. J., Ding, C., Zhang, X., Baloch, Z., Huang, Y., Tang, Y., Li, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16173-0 · Cited by 46
CRISPR-based strategies for targeted transgene knock-in and gene correction
Lau, C., Tin, C., & Suh, Y. (2020) · Faculty Reviews · doi:10.12703/r/9-20 · Cited by 51
Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing
Zhang, Y., Long, C., Bassel‐Duby, R., & Olson, E. N. (2018) · Physiological Reviews · doi:10.1152/physrev.00046.2017 · Cited by 45
“Programmable nucleases such as the CRISPR/Cas system have been demonstrated to be effective in precise correction of pathogenic mutations found in the human embryo (176, 221, 234, 388).”
BackgroundCRISPR–Cas9 gene editing induced complex on-target outcomes in human cells
Wen, W., & Zhang, X. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.002 · Cited by 42
Al-Ouqaili, M. T. S., Ahmad, A., Jwair, N. A., & Al-Marzooq, F. I. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1588446 · Cited by 55
Musunuru, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.002 · Cited by 44
Hoes, M. F., Bömer, N., & van der Meer, P. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0052 · Cited by 48
Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment
Cheng, Z., Fang, T., Huang, J., Guo, Y., Alam, M., & Qian, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.722340 · Cited by 54
“Genome editing CRISPR/Cas9 mutated gene repaired by homology-directed repair with a repair template genetic correction in HCM hiPSC1-3 (55–57), and correct HCM caused by a GAGT-deletion in exon 16 of the MYBPC3 gene (58).”
BackgroundCRISPR-M: Predicting sgRNA off-target effect using a multi-view deep learning network
Sun, J., Guo, J. H., & Liu, J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011972 · Cited by 41
Synergizing CRISPR/Cas9 off-target predictions for ensemble insights and practical applications
Zhang, S., Li, X., Lin, Q., & Wong, K. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty748 · Cited by 43
CRISPR babies: when will the world be ready?
Ledford, H. K. (2019) · Nature · doi:10.1038/d41586-019-01906-z · Cited by 39
Molecular Diagnosis of Hypertrophic Cardiomyopathy (HCM): In the Heart of Cardiac Disease
Melas, M., Beltsios, E. T., Adamou, A., Koumarelas, K. E., & McBride, K. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010225 · Cited by 38
“Simultaneous injection of a mutationspecific CRISPR/Cas9 system during the early metaphase resulted in the successful editing of the mutation [58].”
BackgroundHarnessing CRISPR to combat human viral infections
Buhr, H., & Lebbink, R. J. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.06.002 · Cited by 37
CRISPR babies: a view from the centre of the storm
Lovell-Badge, R. H. (2019) · Development · doi:10.1242/dev.175778 · Cited by 42
Researching the future: scenarios to explore the future of human genome editing
Selin, C. L., Lambert, L. M., Morain, S. R., Nelson, J. P., Barlevy, D., Farooque, M., Manley, H., & Scott, C. T. (2023) · BMC Medical Ethics · doi:10.1186/s12910-023-00951-8 · Cited by 37
“Notably, experiments have tested CRISPR-based germ-line editing to intervene in heritable disease in non-viable human embryos [8–10] and, as widely reported, former Southern University of Science and Technology researcher He Jiankui claimed in late 2018 to have modified CCR5 genes in two embryos…”
BackgroundEthical issues in genetic modification and why application matters
Munsie, M., & Gyngell, C. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.05.002 · Cited by 41
Revising, Correcting, and Transferring Genes
Cwik, B. (2020) · The American Journal of Bioethics · doi:10.1080/15265161.2020.1783024 · Cited by 38
“Researchers have explored uses of germline gene editing to target mutations in the HBB and MYBPC3 genes, mutations which cause (in respective order) beta thalassemia and hypertrophic cardiomyopathy (Liang et al. 2015; Ma et al. 2017).”
BackgroundOttaviani, A., Mansour, D., Molinari, L. V., Galanti, K., Mantini, C., Khanji, M. Y., Chahal, C. A. A., Zimarino, M., Renda, G., Sciarra, L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175710 · Cited by 44
“Importantly, this technique also eliminated mosaicism, a phenomenon where sister cells within the same embryo possess different genotypes [103].”
BackgroundSomitic positional information guides self-organized patterning of snake scales
Tzika, A. C., Ullate‐Agote, A., Zakany, S., Kummrow, M., & Milinkovitch, M. C. (2023) · Science Advances · doi:10.1126/sciadv.adf8834 · Cited by 43
Gómez, K., Duran, P., Tonello, R., Allen, H. N., Boinon, L., Calderón‐Rivera, A., Loya‐López, S., Nelson, T. S., Ran, D., Moutal, A., et al. (2023) · Pain · doi:10.1097/j.pain.0000000000002970 · Cited by 33
Recent advances in mammalian reproductive biology
Wen, L., Liu, Q., Xu, J.-J., Liu, X., Shi, C.-Y., Yang, Z., Zhang, Y., Xu, H., Liu, J., Yang, H., et al. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-1572-7 · Cited by 35
Filho, E. M. D. S., Fernandes, F. D. A., Soares, C. L. D. A., Seixas, F. L., dos Santos, A. A. S. M. D., Gismondi, R. A., Mesquita, E. T., & Mesquita, C. T. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20180431 · Cited by 70
Martin, L. F., Moutal, A., Cheng, K., Washington, S. M., Calligaro, H., Goel, V., Kranz, T., Largent-Milnes, T. M., Khanna, R., Patwardhan, A., et al. (2021) · The Journal of Pain · doi:10.1016/j.jpain.2021.05.006 · Cited by 28
Super-Mendelian inheritance mediated by CRISPR/Cas9 in the female mouse germlinePreprint
Grunwald, H. A., Gantz, V. M., Poplawski, G. H. D., Xu, X., Bier, E., & Cooper, K. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/362558 · Cited by 33
Self-citationDesigning Ethical Trials of Germline Gene Editing
Cwik, B. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1711000 · Cited by 32
Exosomes for CRISPR-Cas9 Delivery: The Cutting Edge in Genome Editing
Aslan, C., Zolbanin, N. M., Faraji, F., & Jafari, R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00932-7 · Cited by 37
“Double-strand breaks (DSBs) in the mutated allele were repaired using the homologous non-mutated maternal copy as a template [150].”
The technical risks of human gene editing
Davies, B. (2019) · Human Reproduction · doi:10.1093/humrep/dez162 · Cited by 39
Programming PAM antennae for efficient CRISPR-Cas9 DNA editing
Wang, F., Hao, Y., Li, Q., Li, J., Zhang, H., Zhang, X., Wang, L., Bustamante, C., & Fan, C. (2020) · Science Advances · doi:10.1126/sciadv.aay9948 · Cited by 36
The dawn of non-human primate models for neurodevelopmental disorders
Aida, T., & Feng, G. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.05.040 · Cited by 32
“2) Allele-specific targeting often induces homozygous conversion of heterozygous alleles by interhomolog repair (recombination between two homologous chromosomes) [35,45].”
BackgroundPast, present and future of ICSI in livestock species
Briski, O., & Salamone, D. (2022) · Animal Reproduction Science · doi:10.1016/j.anireprosci.2022.106925 · Cited by 43
CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Wu, W.-H., Tsai, Y.-T., Huang, I.-W., Cheng, C.-H., Hsu, C., Cui, X., Ryu, J., Quinn, P. M. J., Caruso, S. M., Lin, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.010 · Cited by 37
The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP‐C
Suay‐Corredera, C., & Alegre‐Cebollada, J. (2022) · FEBS Letters · doi:10.1002/1873-3468.14301 · Cited by 32
Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies
Nguyen, Q., Lim, K. R. Q., & Yokota, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030733 · Cited by 35
Hernández‐Terán, A., Wegier, A., Benítez, M., Lira, R., & Escalante, A. E. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.02030 · Cited by 31
“…overcome the problem of position effects through the use of CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) technologies, which guarantees a more accurate genetic modification through a precise insertion in known locations within the target genomes (Ma et al., 2017).”
BackgroundGlobal Governance of Human Genome Editing: What Are the Rules?
Marchant, G. E. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111320-091930 · Cited by 42
Precision Medicine in Cardiovascular Disease: Genetics and Impact on Phenotypes
Semsarian, C., Ingles, J., Ross, S. B., Dunwoodie, S. L., Bagnall, R. D., & Kovacic, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.071 · Cited by 40
Kherraf, Z., Conne, B., Amiri‐Yekta, A., Christou‐Kent, M., Coutton, C., Escoffier, J., Nef, S., Arnoult, C., & Ray, P. F. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.03.002 · Cited by 37
Building Capacity for a Global Genome Editing Observatory: Institutional Design
Saha, K., Hurlbut, J. B., Jasanoff, S., et al. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.04.008 · Cited by 31
Li, J.-J., Lin, X., Tang, C., Lu, Y., Hu, X., Zuo, E., Li, H., Ying, W., Sun, Y., Lai, L., et al. (2019) · National Science Review · doi:10.1093/nsr/nwz131 · Cited by 33
FREQUENT GENE CONVERSION IN HUMAN EMBRYOS INDUCED BY DOUBLE STRAND BREAKSPreprint
Liang, D., Gutiérrez, N. M., Chen, T., Lee, Y., Park, S.-W., Ma, H., Koski, A., Ahmed, R., Darby, H., Li, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.19.162214 · Cited by 33
“NHEJ is active throughout the cell cycle, while HDR is confined to late S/G2 phase (1).”
BackgroundSelf-citationEthics assessment in research proposals adopting CRISPR technology
Hirsch, F., Iphofen, R., & Koporc, Z. (2019) · Biochemia Medica · doi:10.11613/bm.2019.020202 · Cited by 30
“Despite the limitations of the approach chosen by these researchers, this study demonstrated that human embryonic cells can be changed in a simple way, and an article published by an American team in collaboration with Korean scientists followed, reinforcing the idea that human germ cells could be changed by the CRISP…”
Backgroundγ2 GABAAR Trafficking and the Consequences of Human Genetic Variation
Lorenz‐Guertin, J. M., Bambino, M. J., & Jacob, T. C. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00265 · Cited by 34
Embryo-mediated genome editing for accelerated genetic improvement of livestock
McLean, Z. L., Oback, B. J., & Laible, G. (2020) · Frontiers of Agricultural Science and Engineering · doi:10.15302/j-fase-2019305 · Cited by 36
“Since mosaic embryos with more than two alleles are commonly observed, the editing could be continuing throughout subsequent cleavage divisions([40]).”
BackgroundLsh/HELLS is required for B lymphocyte development and immunoglobulin class switch recombination
He, Y., Ren, J., Xu, X., Ni, K., Schwader, A., Finney, R., Wang, C., Sun, L., Klarmann, K. D., Keller, J. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004112117 · Cited by 35
“This has implications for future treatment of ICF patients, since, for example, genome editing of stem cells becomes a potential therapeutic strategy in the treatment of ICF4 patients (45).”
BackgroundSelf-citationOff- and on-target effects of genome editing in mouse embryos
Ayabe, S., NAKASHIMA, K., & Yoshiki, A. (2018) · Journal of Reproduction and Development · doi:10.1262/jrd.2018-128 · Cited by 32
Machine learning in the estimation of CRISPR-Cas9 cleavage sites for plant system
Das, J., Kumar, S., Mishra, D. C., Chaturvedi, K. K., Paul, R. K., & Kairi, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1085332 · Cited by 33
“Though techniques have been extensively used in a wide variety of cells, tissues and organisms (Sander and Joung 2014; Ma et al., 2017; Musunuru 2017) but CRISPR-Cas9 is the most widely used method by researchers worldwide.”
BackgroundMethodTak, I.-U.-R., Ali, F., Dar, J. S., Magray, A. R., Ganai, B. A., & Chishti, M. Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811913-6.00001-1 · Cited by 44
CRISPR Craze to Transform Cardiac Biology
van Kampen, S. J., & van Rooij, E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.008 · Cited by 32
“Importantly, these studies demonstrated similar levels of gene disruption for all these targets, underscoring the possibility that certain genes are more sensitive towards genetic modifications than others (see Clinician’s Corner).”
BackgroundInfluentialSudden cardiac death in the young: a genetic destiny?
Thiene, G. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-s17 · Cited by 35
Biotechnology, communication and the public: Keys to delve into the social perception of science
Brossard, D. (2019) · Mètode: Revista de difusió de la investigació de la Universitat de Valencia · doi:10.7203/metode.9.11347 · Cited by 32
“Applications in the human context are also becoming reality, with the journal Nature announcing in August 2017 that for the first time, a gene responsible for heart failure had been successfully edited in a human embryo using CRISPR/ Cas9 (Ma et al., 2017).”
BackgroundRETIRED: Financial compensation of oocyte donors: an Ethics Committee opinion
Daar, J., Benward, J. M., Collins, L. R., et al. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.09.040 · Cited by 28
Xu, M. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00410-6 · Cited by 29
JEDWAB, A., Vears, D. F., Tse, C., & Gyngell, C. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-0810-2 · Cited by 31
Iavarone, M., Monda, E., Vritz, O., Albert, D. C., Rubino, M., Verrillo, F., Caiazza, M., Lioncino, M., Amodio, F., Guarnaccia, N., et al. (2022) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2022.06.003 · Cited by 31
The Bioethics of Space Exploration
Szocik, K. (2023) · doi:10.1093/oso/9780197628478.001.0001 · Cited by 35
CRISPR/Cas9 increases mitotic gene conversion in human cells
Javidi-Parsijani, P., Lyu, P., Makani, V. S., Sarhan, W. M., Yoo, K. W., El-Korashi, L. A., Atala, A., & Lu, B. (2020) · Gene Therapy · doi:10.1038/s41434-020-0126-z · Cited by 31
A perspective on “cure” for Rett syndrome
Clarke, A. J., & Abdala, A. P. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0786-6 · Cited by 29
Congenital eye anomalies: More mosaic than thought?
Ohuchi, H., Sato, K., Habuta, M., Fujita, H., & Bando, T. (2018) · Congenital Anomalies · doi:10.1111/cga.12304 · Cited by 30
“Furthermore, for genome editing employed in human embryos as a tool for correcting mutations in hereditary diseases, edited cells, and unedited cells should not be mixed in various tissues and organs.(150,151) To lower mosaicism, three improvements can be made as follows: (1) transferring Cas9 protein instead of mRNA;…”
Human cleaving embryos enable robust homozygotic nucleotide substitutions by base editors
Zhang, M., Zhou, C., Yu, W., Xu, C., Pan, H., Ying, W., Sun, Y., Sun, Y. W., Xiao, Q., Yao, N., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1703-6 · Cited by 27
Self-citationCarey, K., Ryu, J., Uh, K., Lengi, A. J., Clark‐Deener, S., Corl, B. A., & Lee, K. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0517-7 · Cited by 28
Attitudes of people with inherited retinal conditions toward gene editing technology
Hoffman‐Andrews, L., Mazzoni, R., Pacione, M., Garland‐Thomson, R., & Ormond, K. E. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.803 · Cited by 33
“The first clinical trials using somatic gene editing technology are already underway (Kaiser, 2017), as are early forays into gene editing in embryos (Cyranoski & Ledford, 2018; Ma et al., 2017; Zeng et al., 2018).”
MethodGenetic therapies, human genetic enhancement, and … eugenics?
Friedmann, T. (2019) · Gene Therapy · doi:10.1038/s41434-019-0088-1 · Cited by 30
PREIMPLANTATION GENETIC TESTING: Preimplantation genetic testing for polygenic disease risk
Treff, N. R., Marin, D., Lello, L., Hsu, S., & Tellier, L. C. A. M. (2020) · Reproduction · doi:10.1530/rep-20-0071 · Cited by 29
“New research involving the creation of gene-edited-embryo-derived embryonic stem cells (Ma et al. 2017) may be instrumental in the development of rigorous safety and efficacy data, but also to aid in development of the necessary genome-wide PGT methodologies.”
Abbas, M. T., Ali, N. B., Farina, J., Mahmoud, A., Pereyra, M., Scalia, I. G., Kamel, M., Barry, T., Lester, S. J., Cannan, C. R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12030682 · Cited by 31
Precision medicine ― A promising, yet challenging road lies ahead
Malod‐Dognin, N., Petschnigg, J., & Pržulj, N. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.10.003 · Cited by 30
Phaneuf, C. R., Seamon, K. J., Eckles, T., Sinha, A., Schoeniger, J. S., Harmon, B., Meagher, R. J., Abhyankar, V. V., & Koh, C. (2019) · Analytical Methods · doi:10.1039/c8ay02726a · Cited by 30
Lumpers and splitters: the bumpy road to precision medicine
Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz644 · Cited by 27
Fuziwara, C. S., Saito, K. C., & Kimura, E. T. (2019) · Thyroid · doi:10.1089/thy.2018.0601 · Cited by 28
Mianné, J., Nasri, A., Van, C. N., Bourguignon, C., Fieldès, M., Ahmed, E., Duthoit, C. T., Martin, N., Parrinello, H., Louis, A., et al. (2022) · BMC Biology · doi:10.1186/s12915-021-01214-x · Cited by 24
Big data-driven precision medicine: Starting the custom-made era of iatrology
Song, C. M., Kong, Y., Huang, L., Luo, H., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110445 · Cited by 27
Transformer-based anti-noise models for CRISPR-Cas9 off-target activities prediction
Guan, Z., & Jiang, Z. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad127 · Cited by 29
Limitations of gene editing assessments in human preimplantation embryos
Liang, D., Mikhalchenko, A. E., Ma, H., Gutiérrez, N. M., Chen, T., Lee, Y., Park, S.-W., Tippner-Hedges, R., Koski, A., Darby, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36820-6 · Cited by 32
Self-citationPhysiology of cardiac development: from genetics to signaling to therapeutic strategies
Sun, C., & Kontaridis, M. I. (2017) · Current Opinion in Physiology · doi:10.1016/j.cophys.2017.09.002 · Cited by 33
Efficient Human Genome Editing Using SaCas9 Ribonucleoprotein Complexes
Wang, Y., Wang, B., Xie, H., Ren, Q., Liu, X., Li, F., Lv, X., He, X., Cheng, C., Deng, R., et al. (2019) · Biotechnology Journal · doi:10.1002/biot.201800689 · Cited by 29
Genome-wide studies of heart failure and endophenotypes: lessons learned and future directions
van der Ende, M. Y., Said, M. A., van Veldhuisen, D. J., Verweij, N., & van der Harst, P. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy083 · Cited by 27
Opportunities in biotechnology
Gartland, K. M. A., & Gartland, J. S. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.06.303 · Cited by 34
“A team led by Shoukhrat Matalipov, has corrected the dominant pathogenic gene mutation MyBPC3 in viable human embryos (Ma et al., 2017).”
BackgroundSpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice
Ajina, R., Zamalin, D., Zuo, A., Moussa, M., Catálfamo, M., Jablonski, S. A., & Weiner, L. M. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1577127 · Cited by 24
“Furthermore, by harnessing the ability to change a faulty gene itself, the introduction of CRISPR-Cas9 technology could be employed as a therapeutic for hereditary or mutation-based conditions.(12) In spite of its promise in human health and in vivo applications, the CRISPR-Cas9 system has some potential pitfalls.”
BackgroundMoving Beyond ‘Therapy’ and ‘Enhancement’ in the Ethics of Gene Editing
Cwik, B. (2019) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180119000641 · Cited by 34
Assessing Public Opinion on CRISPR-Cas9: Combining Crowdsourcing and Deep Learning
Müller, M., Schneider, M., Salathé, M., & Vayena, E. (2020) · Journal of Medical Internet Research · doi:10.2196/17830 · Cited by 31
“Peak c coincides with the publication of a study that reported the correction of a mutation in human embryos [57], causing widespread media attention and, as before, did not cause a drop in sentiment.”
Result
Metadata
- Authors
- Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., Darby, H., Van Dyken, C., Li, Y., Kang, E., Park, A.-R., Kim, D., Kim, S.-T., Gong, J., Gu, Y., Xu, X., Battaglia, D., Krieg, S. A., Lee, D. M., Wu, D. H., Wolf, D. P., Heitner, S. B., Belmonte, J. C. I., Amato, P., Kim, J.-S., Kaul, S., & Mitalipov, S.
- Affiliations
- Oregon Health & Science University (US)
- Institute for Basic Science (KR)
- Salk Institute for Biological Studies (US)
- Seoul National University (KR)
- BGI Group (China) (CN)
- Corresponding author
- Amato, Paula
- Kim, Jin-Soo
- Kaul, Sanjiv
- Mitalipov, Shoukhrat
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7668
- Pages
- 413-419
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2740810575
- Cited by
- 992
- References
- 48
- Citations by year
- 2026: 22 · 2025: 50 · 2024: 47 · 2023: 93 · 2022: 75 · 2021: 107 · 2020: 135 · 2019: 155 · 2018: 217 · 2017: 88
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2017-10-02)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Oregon Health and Science University
- Leona M. and Harry B. Helmsley Charitable Trust
- Consorzio Interuniversitario Biotecnologie
- Moxie Foundation
- Government of Jiangxi Province
- Institute for Basic Science (IBSR021-D1, R021-D1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- germline editing, CRISPR/Cas9, MYBPC3 mutation, hypertrophic cardiomyopathy, preimplantation embryo, homology-directed repair, mosaicism, DNA double-strand break repair, cell cycle timing, preimplantation genetic diagnosis, off-target mutations
- MeSH terms
- Gene Editing, Myosin Binding Protein C, Adult, Alleles, Blastocyst, Carrier Proteins, Cell Division, Embryo, Mammalian, Genetic Complementation Test, Heterozygote, Homozygote, Humans, Male, Mosaicism, Mutation, Templates, Genetic, Zygote, S Phase, Gene Targeting, DNA Breaks, Double-Stranded, Recombinational DNA Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.